NovaBay Pharmaceuticals (NBY)
(Delayed Data from AMEX)
$2.51 USD
-0.06 (-2.33%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $2.57 +0.06 (2.39%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth A Momentum B VGM
Brokerage Reports
NovaBay Pharmaceuticals, Inc. [NBY]
Reports for Purchase
Showing records 101 - 109 ( 109 total )
Company: NovaBay Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: NovaBay Pharmaceuticals, Inc.
Industry: Medical - Drugs
Transferring Coverage; Rating, PT and Estimates Under Review
Provider: Roth Capital Partners, Inc.
Analyst: MARTIN J
Company: NovaBay Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: NovaBay Pharmaceuticals, Inc.
Industry: Medical - Drugs
Business Update Suggests Potential Pipeline Acceleration - Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: MOSKOWITZ D
Company: NovaBay Pharmaceuticals, Inc.
Industry: Medical - Drugs
We reiterate our BUY recommendation and our 12-month target price of $4.25
Provider: GRIFFIN SECURITIES, INC.
Analyst: MARKEY K
Company: NovaBay Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: NovaBay Pharmaceuticals, Inc.
Industry: Medical - Drugs
We reiterate our BUY recommendation and maintain our price target of $9.00.
Provider: GRIFFIN SECURITIES, INC.
Analyst: MARKEY K
Company: NovaBay Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: NovaBay Pharmaceuticals, Inc.
Industry: Medical - Drugs
We reiterate our BUY recommendation and our target price of $9.00 per share
Provider: GRIFFIN SECURITIES, INC.
Analyst: MARKEY K